Aizen Therapeutics
Aizen Therapeutics operates as a biotechnology firm focusing on the discovery of Mirror Peptides, synthetic structures composed entirely of D-amino acids designed to expand therapeutic options beyond natural proteins. The company’s DaX™ platform, developed by Caltech Professor David Van Valen, leverages generative AI along with guided diffusion, computational binding models, and GPU compute to engineer novel peptide structures that bind clinical targets. This AI-driven process enables design-build-test cycles in roughly four weeks, with validated hit rates that exceed conventional benchmarks; the platform also supports multi-objective optimization, balancing traits like specificity, half-life, and solubility simultaneously. Aizen advances its pipeline through stages such as discovery, IND-enabling studies, and Phase 1 trials across areas including neurological disorders, oncology, and genetic diseases.